Small Pharma Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- George Tziras
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6-8 Bonhill Street London United Kingdom EC2A 4BX
- IPO Date
- Jun 7, 2021
- Website
- smallpharma.com
- Similar Companies
- Business
- Small Pharma Inc. (DMTTF) is a clinical-stage biotechnology company that develops short-acting psychedelic-assisted therapies, primarily N,N-dimethyltryptamine (DMT)-based treatments combined with psychotherapy, for mental health disorders including major depressive disorder (MDD), PTSD and anxiety; its lead product candidate is SPL026 (DMT placebo-controlled formulation) in Phase IIA trials for MDD, with preclinical programs encompassing SPL028 (prolonged DMT series), SPL029 (oral DMT series) and SPL801 (oral 6-hydroxynorketamin formulation). Founded in 2015 and headquartered in London, United Kingdom, the company operates in the neuropharmaceutical sector with a focus on research and development of patent-protected tryptamine compounds targeting patients unresponsive to conventional antidepressants. In October 2023, Small Pharma was acquired by Cybin Inc. and now operates as a wholly-owned subsidiary, integrating its DMT portfolio with Cybin's psychedelic therapeutics pipeline to enhance clinical development and create operational synergies in neuropsychiatry. The combined entity advances global operations across Canada, the United States, the United Kingdom and Europe, with Small Pharma's assets contributing to Cybin's programs in depression and anxiety treatment.
Small Pharma Reports Fiscal Second Quarter 2024 Highlights
Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
Disposition of Common Shares of Small Pharma Inc.
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
Cybin to Acquire Small Pharma Inc.
Small Pharma Reports Fiscal First Quarter 2024 Highlights
Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
Small Pharma to Present at Cowen's 43rd Annual Health Care Conference
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
Small Pharma to Participate in Upcoming September Investor Conferences
Canaccord Genuity repeats 'Speculative Buy' rating and $1.00 price target on Small Pharma following publication of its full-year results
Small Pharma publishes year to February 28, 2022, results showing cash on hand of C$40.7M
Small Pharma To Present at the Jefferies Healthcare Conference in New York City on June 10, 2022
Small Pharma to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6, 2021